Clinical trials: Neoplasms, Germ Cell and Embryonal
High-Grade Glioma (WHO III-IV)
FG001 Near-Infrared Fluorescence Imaging During Tumor Resection in Newly Diagnosed High-Grade Glioma
This clinical trial aims to determine if FG001 can assist surgeons in identifying the difference between tumor and healthy tissue during surgery in participants with newly diagnosed high-grade glioma.
- Trial name
- NCT07609472
- Testing
- FG001
- Where
- 5 sites in United States
- Volunteers
- 76 people
- Sponsor
- FluoGuide A/S
Lymphedema of Leg, Cancer of Cervix
High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs
The aim of the study is to explore the feasibility and safety of High Intensity Interval Training on a stationary bike for patients with lymphedema in the lower limbs and the role of compression garments during exercise.
- Conditions
- Lymphedema of Leg, Cancer of Cervix, Cancer, Ovarian, Cancer, Endometrial
- Trial name
- NCT03653819
- Testing
- First exercise session + compression, First exercise session - compression
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Herlev and Gentofte Hospital
Lentigo Maligna
Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream
This study investigates the efficacy of photodynamic therapy (PDT) in the treatment of lentigo maligna (LM). Hyperspectral imaging system (HIS) will be used to determine the margins of LM and to rule out possible invasion.
- Trial name
- LM PDT (NCT02685592)
- Testing
- 5-aminolevulinic acid nanoemulsion
- Where
- Finland
- Volunteers
- 10 people
- Sponsor
- Joint Authority for Päijät-Häme Social and Health Care
Metastatic Melanoma, Metastatic Renal Cell Cancer
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
Background: -This study uses an experimental cancer treatment that uses the patient s own lymphocytes (type of white blood cell), which are specially selected and genetically modified to target and destroy their tumor.
- Conditions
- Metastatic Melanoma, Metastatic Renal Cell Cancer, Metastatic Cancer
- Trial name
- NCT00670748
- Testing
- Anti-NY ESO-1 T-cell receptor PBL, aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Neuroendocrine Carcinoma
Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II
This study is the first randomized, open-label, national, multicenter, phase II study assessing the efficacy and safety of OCLU in subjects with pretreated progressive pancreatic, inoperable, somatostatin receptor positive, well…
- Trial name
- OCCLURANDOM (NCT02230176)
- Testing
- Sunitinib, 177Lu-DOTA0-Tyr3-Octreotate
- Where
- France
- Volunteers
- 84 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
- Conditions
- Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney, Epithelioid Sarcoma, Chordoma (Poorly Differentiated or De-differentiated)
- Trial name
- NCT04416568
- Testing
- Nivolumab, Ipilimumab
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Trophoblastic Neoplasms, Uterine Neoplasms
A Trial for Patients With Gestational Trophoblastic Disease
This phase II study is evaluating the activity of Pemetrexed in patients diagnosed with low risk Gestational Trophoblastic Tumor (GTT) that have failed prior treatment.
- Conditions
- Trophoblastic Neoplasms, Uterine Neoplasms, Hydatidiform Mole, Choriocarcinoma
- Trial name
- NCT00190918
- Testing
- Pemetrexed
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Eli Lilly and Company
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)
This study will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD) in children with newly diagnosed DIPG or DMG. All patients will receive BXQ-350 by intravenous (IV) infusion and radiation therapy.
- Trial name
- KONQUER (NCT04771897)
- Testing
- BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance, BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Bexion Pharmaceuticals, Inc.
Carcinoma, Glioblastoma
MRinRT: Swansea University and SWWCC Collaboration Study.
The aim of this study is to learn whether using MRI (magnetic resonance imaging) scans to plan radiotherapy is better than using CT (computed tomography) scans alone.
- Conditions
- Carcinoma, Glioblastoma, Radiotherapy, MRI
- Trial name
- MRinRT (NCT07365124)
- Testing
- MRI
- Where
- United Kingdom
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Swansea Bay University Health Board
Metastatic Melanoma
Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma
Purpose of investigation: Primary hypotheses: Immunization of patients with 4 melanoma antigen peptides will induce augmented specific IFN-y-producing CD8+ T cells against all 4 antigens simultaneously.
- Trial name
- NCT00203879
- Testing
- MAGE-3/Melan-A/gp100/NA PBMC, rhIL-12 (drug), MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Chicago
Relapsed / Recurrent Germ Cell Tumors
A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors
The purpose of this study is to find out if the combination of an mTOR inhibitor (sirolimus) with an EGFR inhibitor (erlotinib) is effective at treating relapsed or refractory germ cell tumors, and to find out what the…
- Trial name
- NCT01962896
- Testing
- Erlotinib, Sirolimus
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Theodore Laetsch
Malignant Glioma
AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma
The trial will address safety and tolerability of the combination of the IDH1R132H-specific vaccine with checkpoint blockade and seeks to explore predictive biomarkers for response to checkpoint blockade in post-treatment tumor…
- Trial name
- AMPLIFY-NEOVAC (NCT03893903)
- Testing
- IDH1R132H peptide vaccine, Avelumab
- Where
- 10 sites in Germany
- Volunteers
- 69 people
- Sponsor
- German Cancer Research Center
Melanoma
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
The purpose of this study is to investigate the pharmacokinetics (PK) similarity of Bmab1700 (an intended nivolumab biosimilar), compared with United States (US)-licensed Opdivo, in participants after complete surgical removal of…
- Trial name
- NCT07476326
- Testing
- Bmab1700, Opdivo
- Where
- 46 sites in Brazil, Chile and 8 more
- Volunteers
- 120 people
- Sponsor
- Biocon Biologics UK PLC
Brain and Central Nervous System Tumors
ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of glioblastoma multiforme.
- Trial name
- NCT00016991
- Testing
- gefitinib
- Where
- United States
- Sponsor
- Duke University
Brain Metastases, Glioma of Brain
Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases
Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) is a potentially powerful diagnostic tool for the management of brain cancer and other conditions in which the blood-brain barrier is compromised.
- Conditions
- Brain Metastases, Glioma of Brain, Brain Tumor, Metastatic Melanoma
- Trial name
- NCT03698162
- Testing
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Bevacizumab Injection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Southern California
Melanoma (Skin)
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003346
- Testing
- acetaminophen, acetylcysteine, carmustine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Merkel Cell Carcinoma
Targeted Therapy and Avelumab in Merkel Cell Carcinoma
10.17 GoTHAM is intended as a signal-seeking, biomarker, phase Ib/II study that will evaluate the safety and anti-tumour activities of the novel combination of avelumab with 177-Lu-DOTATATE (a type of peptide receptor…
- Trial name
- GoTHAM (NCT04261855)
- Testing
- Avelumab, External Beam Radiation Therapy (EBRT), Lutetium-177 (177Lu)-DOTATATE
- Where
- 10 sites in Australia
- Volunteers
- 19 people
- Sponsor
- Melanoma and Skin Cancer Trials Limited
Melanoma, Breast Cancer
Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)
Coxsackie A21 (CVA21) virus is to be administered by IV infusion to patients with Stage 4 melanoma, prostate and breast cancer. This is a dose escalation, safety study.
- Conditions
- Melanoma, Breast Cancer, Prostate Cancer
- Trial name
- PSX-X04 (NCT00636558)
- Testing
- CVA21
- Where
- 2 sites in Australia
- Volunteers
- 8 people
- Sponsor
- Viralytics
Gestational Trophoblastic Neoplasia, Complete Hydatiform Mole
Uterine Artery Doppler Flow Velocimetry Parameters for Predicting the Occurrence of Persistent Gestational Trophoblastic Neoplasia After Evacuation of Complete Hydatiform Mole
This Prospective study will be conducted To copare uterine blood flow using Doppler ultrasound before and after evacuation of hydatiform mole between female patients with remissions and those with development of post-molar…
- Trial name
- NCT07333326
- Volunteers
- 175 people
- Sponsor
- Minia University
Melanoma (Skin Cancer), Nevi and Melanomas
Precision Medicine for L/GCMN and Melanoma 2
The primary objective is to evaluate the possibility of using minimally and non-invasive technologies (skin patch and breath analyzer) based on the detection of volatile organic compounds (VOCs) for the early identification of…
- Conditions
- Melanoma (Skin Cancer), Nevi and Melanomas, Congenital Melanocytic Nevus
- Trial name
- Precis-mel 2 (NCT06605443)
- Testing
- Breath analyzer, Skin patch, Liquid biopsy
- Where
- 3 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.